Last reviewed · How we verify
ergocalciferol (vitamin D2)
Ergocalciferol (vitamin D2) is converted in the body to its active form, which binds to the vitamin D receptor to regulate calcium and phosphate homeostasis and support bone health and immune function.
Ergocalciferol (vitamin D2) is converted in the body to its active form, which binds to the vitamin D receptor to regulate calcium and phosphate homeostasis and support bone health and immune function. Used for Vitamin D deficiency, Hypoparathyroidism, Rickets.
At a glance
| Generic name | ergocalciferol (vitamin D2) |
|---|---|
| Also known as | D2 |
| Sponsor | Atlanta VA Medical Center |
| Drug class | Vitamin D supplement |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Bone Health |
| Phase | FDA-approved |
Mechanism of action
Ergocalciferol is a plant-derived form of vitamin D that undergoes hydroxylation in the liver and kidneys to form the active metabolite calcitriol. This active form binds to the vitamin D receptor (VDR), a nuclear receptor that modulates gene expression to increase intestinal calcium absorption, regulate serum calcium and phosphate levels, and support bone mineralization. Additionally, vitamin D receptor signaling plays important roles in immune cell differentiation and function.
Approved indications
- Vitamin D deficiency
- Hypoparathyroidism
- Rickets
- Osteomalacia
- Hypophosphatemia
Common side effects
- Hypercalcemia
- Hypercalciuria
- Nausea
- Vomiting
- Constipation
- Weakness
Key clinical trials
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn (PHASE2)
- Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease (PHASE2)
- High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma (NA)
- Vitamin D Homeostasis in Sarcoidosis (PHASE4)
- Vitamin D Deficiency in Adults Following a Major Burn Injury (PHASE4)
- Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy (PHASE2)
- Relationship Between Serum Vitamin D and Atherosclerosis in Hemodialysis Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ergocalciferol (vitamin D2) CI brief — competitive landscape report
- ergocalciferol (vitamin D2) updates RSS · CI watch RSS
- Atlanta VA Medical Center portfolio CI